Below are abstracts from the asco conferences.

Asco 2018

ASCO General Meeting Poster TPS4156 – SM-88 in Advanced Cancers of the Pancreas

ASCO General Meeting Poster e13100 – SM-88 Efficacy and Safety in Metastatic Breast Cancers

ASCO General Meeting Poster e24072 – Prospective Comparison of Invasive Circulating Tumor Cells (iCTCs) vs PSA and mPFS in Prostate Cancer (PC) Treated with SM-88

ASCO General Meeting Poster e14535 – SM-88 Efficacy Across Multiple High-Risk Factors

ASCO General Meeting Poster e14528 – Comparison of SUV and RECIST Responses in Cancers Treated with SM-88

ASCO GU Poster 2018 – Phase II Trial of SM-88 in Non-Metastatic Biochemical Recurrent Prostate Cancer

ASCO GI Poster 2018 – SM-88 Therapy in Patients with Advanced or Metastatic Pancreatic Cancer


Asco 2017

ASCO Poster 2017 – A Phase 1b/2, Open-Label, Dose Escalation Study to Evaluate the Safety,
Pharmacokinetics, and Efficacy of TYME-88 (SM-88) in Patients with Prostate Cancer

A phase Ib/II, open-label, dose escalation study to evaluate the safety, pharmacokinetics, and efficacy of SM88 in patients with prostate cancer.
Abstract: TPS2615

SMK/SM88 toxicity, efficacy, and patient-reported outcomes in metastatic pancreas cancer. Abstract: e14060

Phase Ib pharmacokinetics of non-hormonal SM88 in patients with non-metastatic recurrent prostate cancer. Abstract: E14061

SM88/SMK non-hormonal therapy in recurrent or untreated prostate cancer. Abstract: E16540

SM88 in non-metastatic rising PSA-recurrent prostate cancer. Abstract: E16567